en.Wedoany.com Reported - Imugene Ltd presented clinical progress on its Azer-Cel program at the American Society of Clinical Oncology (ASCO) meeting in Chicago, securing an oral presentation slot from over 8,500 submissions. ASCO is one of the largest oncology conferences globally, with a packed audience on the day of the presentation, including hundreds of attendees, some standing during the talk.
Managing Director and CEO Leslie Chong stated that the presented data focused on Imugene's second cohort study, evaluating Azer-Cel in blood cancer patients who had not previously received approved CAR-T therapy. Responses were observed in multiple rare indications, including chronic lymphocytic leukemia (CLL), marginal zone lymphoma, and Waldenström macroglobulinemia. Some patients experienced responses lasting over six to seven months, and one CLL patient progressed from partial response to complete response after approximately five months, a challenging achievement in this disease context.
The engagement from oncologists, investors, and pharmaceutical company representatives indicated growing interest in the program, with the presentation generating significant audience interaction and questions. A key catalyst for Imugene will be the continued enrollment and follow-up of patients in the CAR-T-naïve cohort; as more patients remain in the study, additional durability data could further enhance Azer-Cel's clinical profile. Another important catalyst is the company's BTK inhibitor combination program, with the BTK inhibitor market valued at approximately $12 billion annually. The study is exploring whether concurrent treatment with Azer-Cel can improve outcomes and potentially extend the effectiveness of existing therapies.
Chong expressed the company's excitement about the data and highlighted the enthusiasm of researchers involved in the trial, including Dr. Gupta, who presented the results at ASCO. The conference also provided opportunities to engage with large pharmaceutical companies, an audience that may become increasingly important as clinical development progresses. Management believes Azer-Cel has potential both as a monotherapy and in combination, and collaborations could help bring the treatment to patients more effectively. Imugene will continue patient enrollment and follow-up, and begin treatment in the BTK inhibitor combination study, with the goal of improving and extending patients' lives.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
